COVID-19 and its effects on the digestive system

Abstract

Coronavirus disease 2019 (COVID-19) is caused by infection of the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with typical respiratory symptoms. SARS-CoV-2 invades not only the respiratory system, but also other organs expressing the cell surface receptor angiotensin converting enzyme 2. In particular, the digestive system is a susceptible target of SARS-CoV-2. Gastrointestinal symptoms of COVID-19 include anorexia, nausea, vomiting, diarrhea, abdominal pain, and liver damage. Patients with digestive damage have a greater chance of progressing to severe or critical illness, a poorer prognosis, and a higher risk of death. This paper aims to summarize the digestive system symptoms of COVID-19 and discuss fecal-oral contagion of SARS-CoV-2. It also describes the characteristics of inflammatory bowel disease patients with SARS-CoV-2 infection and discusses precautions for preventing SARS-CoV-2 infection during gastrointestinal endoscopy procedures. Improved attention to digestive system abnormalities and gastrointestinal symptoms of COVID-19 patients may aid health care providers in the process of clinical diagnosis, treatment, and epidemic prevention and control.

Core Tip: Coronavirus infections can cause a series of digestive diseases and may also be accompanied by digestive manifestations. Furthermore, the potential mechanisms of coronavirus disease 2019 (COVID-19) on the digestive system, the fecal-oral contagion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the characteristics of inflammatory bowel disease patients with SARS-CoV-2 infection, and the management during gastrointestinal endoscopy procedures are also discussed. This review provides a new perspective to clinicians for the prevention and treatment of COVID-19.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a neo-type respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously known as 2019-nCoV). SARS-CoV-2 emerged in Wuhan, Hubei Province in late December 2019[1] and quickly spread throughout China and subsequently throughout over 213 countries, evolving into a pandemic and threatening global public health by human-to-human transmission. By December 29, 2020, over 79 million reported cases and over 1.7 million deaths have been confirmed globally since the start of the pandemic[2].

SARS-CoV-2 is a single-stranded positive-sense RNA virus belonging to the β-coronavirus family. SARS-CoV-2 shows over 88% homology with two bat-derived severe acute respiratory syndrome (SARS)-related coronaviruses[3] and is identified as the eighth coronavirus with human infection capacity[4]. Other similar coronaviruses with this capacity include SARS-CoV, which causes severe acute respiratory syndrome, and Middle East respiratory syndrome (MERS-CoV), which causes Middle East respiratory syndrome. In contrast to SARS-CoV and MERS-CoV, the new virus is highly transmissible between individuals even during the pre-clinical phase. It has higher transmission and infection potentiality but a reported lower mortality rate as compared to SARS-CoV and MERS-CoV[5]. Although respiratory compromise with dominant symptoms of fever and cough is the cardinal feature of the disease, involvement of the gastrointestinal (GI) tract and the hepatic system has been increasingly reported. In this review article, we discuss in detail GI symptoms and the role of liver involvement in COVID-19. We also discuss the possible effects of COVID-19 in inflammatory bowel disease (IBD) patients and precautions to be taken during GI endoscopy procedures.

DIGESTIVE TRANSMISSION OF COVID-19 OUTBREAKS

SARS-CoV-2 is spread and transmitted mainly through direct or indirect droplet exposure. The finding of SARS-CoV-2 nucleic acid in patients’ feces indicates that SARS-CoV-2 has the potential to be transmitted through the fecal-oral route. Several studies have reported the presence of viral RNA in feces or anal/rectal swabs of patients with COVID-19[6-9]. In a study about SARS-CoV-2 detection in the specimens of 205 COVID-19 patients, the live virus was detected in 29% of fecal specimens, implying that SARS-CoV-2 may be transmitted by the fecal route[10]. Guan et al[11] found that SARS-CoV-2 RNA was detected in four (6.5%) of 62 stool specimens, and four rectal swabs were positive for SARS-CoV-2 RNA. The percentage of positive stool samples has been reported up to 53.42% among hospitalized patients confirmed with COVID-19[12]. Chen et al[13] reported a special case of an infected COVID-19 patient with a positive virus nucleic acid result in a fecal specimen and negative findings on several pharyngeal and sputum samples. This case report contributes to the understanding of the infection route of SARS-CoV-2 by demonstrating that the virus can grow in the digestive tract and may be capable of spreading through fecal-oral transmission[13]. The duration time of positive stool results ranged from 1 to 12 d and 17 patients continued to have positive results in stool after showing negative results in respiratory samples[12]. Another systematic review and meta-analysis found that viral RNA was detected in stool samples from 48.1% of patients in the study sample, even in stool collected after respiratory samples had produced negative test results[14]. These findings indicate that viral gastrointestinal tract infections and potential fecal transmission may have persisted even after the virus was cleared in the respiratory tract. This positive detection of SARS-CoV-2 in stool specimens was a breakthrough because it demonstrated that the virus could replicate and exist in the digestive tract. The duration of viral nucleic acid in feces is longer than that in respiratory specimens, and the peak of viral load is later. Therefore, clinicians should consider the possibility of viral transmission through the fecal-oral route in the management of COVID-19. The importance of the high detection rate of viral RNA in fecal samples needs to be more carefully considered so that fecal-oral transmission of SARS-CoV-2 can be better controlled and prevented.

GASTROINTESTINAL SYMPTOMS OF COVID-19 PATIENTS

The most prominent clinical presentations of COVID-19 in the existing literature are respiratory symptoms such as fever, cough and sputum, and dyspnea. Digestive system symptoms in COVID-19 patients have been increasingly reported with the accumulation of case data as the pandemic continues to evolve[1,15-21] (Table 1). The most commonly reported gastrointestinal symptoms of the disease are diarrhea, anorexia, nausea, vomiting, abdominal discomfort, and gastrointestinal bleeding. Loss of appetite, diarrhea, and vomiting were the three most frequent digestive symptoms in patients with COVID-19. There have been some reports of a small number of patients presenting only with diarrhea and vomiting without fever or cough[22,23]. In a meta-analysis of 60 studies including 4243 patients, the pooled prevalence of all gastrointestinal symptoms was 17.6%[14]. Eleven studies in the meta-analysis compared the prevalence of gastrointestinal symptoms to COVID-19 disease severity; 11.8% of patients with non-severe COVID-19 and 17.1% of patients with severe COVID-19 had gastrointestinal symptoms, indicating that the prevalence of severe disease was more common in patients with gastrointestinal symptoms[14]. Redd et al[24] similarly found that gastrointestinal symptoms occurred in 61.3% of patients included in the study, and they were the predominant presenting complaint amongst 20.3% of patients. Importantly, gastrointestinal manifestations may be the only initial symptoms in some patients with COVID-19. In the study by An et al[25], 54 patients reported only gastrointestinal symptoms without fever or respiratory symptoms. Six (66.7%) patients had anorexia. None of the cases presented with fever at onset, and all cases presented with digestive symptoms occurring 1-3 d prior to admission[25]. Another study involving 1141 COVID-19 patients found that 183/1141 (16%) presented with GI symptoms only[18]. In addition, digestive symptoms appeared to be associated with worse prognoses. Multiple studies have reported a higher incidence of diarrhea, nausea, or vomiting in patients with severe disease as compared to those with non-severe disease. In addition, there is a connection between the presence of diarrhea and respiratory symptom severity; Li et al[26] reported that more patients with diarrhea required ventilator support and were admitted to the intensive care unit (ICU) than those without diarrhea. Pan et al[27] found that patients with digestive symptoms had a longer time from onset to hospital admission as compared to patients without digestive symptoms. Sixty percent of patients without digestive symptoms recovered and were discharged, while only 34.3% of patients with digestive symptoms recovered[27]. Digestive symptoms appeared to be tied to worse COVID-19 outcomes.

Table 1.

Summary of clinical features of coronavirus disease 2019 patients with digestive symptoms, n (%)

Ref.	Total patients	Diarrhea	Anorexia	Nausea	Vomiting	Abdominal pain
Huang et al[1], 2020	38	1 (2.6)
Chen et al[15], 2020	99	2 (2.0)		1 (1.0)	1 (1.0)
Zhou et al[105], 2020	141	9 (4.7)		7 (3.7)	7 (3.7)
Mao et al[19], 2020	6686	601 (9)	1404 (21)	401 (6)	401 (6)	200 (3)
Guan et al[11], 2020	1999	42 (3.8)		55 (5.0)	55 (5.0)
Pan et al[27], 2020	204	35 (17.2)	4 (2.0)		81 (39.7)	2 (0.98)
Holshue et al[20], 2020	1 (first case)	1 (100)	1 (100)	1 (100)	1 (100)	1 (100)
Luo et al[18], 2020	1141	68 (6.0)	180 (15.8)	134 (11.7)	119 (10.4)	45 (3.9)
Han et al[9], 2020	206	67 (32.5)	112 (49.5)		24 (11.7)	9 (4.4)
Lin et al[106], 2020	95	23 (24.2)	17 (17.9)	17 (17.9)	4 (4.2)	2 (2.1)
Wang et al[32], 2020	138	55 (39.9)	14 (10.1)	14 (10.1)	5 (3.6)	3 (2.2)
Zhang et al[107], 2020	140	17 (12.2)	18 (12.9)	24 (17.3)	7 (5)	8 (5.8)
Liu et al[23], 2020	137	11 (8.0)

This bank of published literature provides robust evidence for GI symptoms as common clinical manifestations of COVID-19. GI symptoms should attract the attention of both patients and doctors. It is crucial for clinicians to be on the alert for atypical symptoms to avoid missed COVID-19 diagnosis.

MECHANISMS OF GASTROINTESTINAL TRACT INVOLVEMENT

Intestinal damage caused by SARS-CoV-2 infection has been verified by autopsy and biopsy. A recent report described the intestinal autopsy from a COVID-19 patient who developed alternating segmental dilatation and stenosis of the small intestine[28]. However, the mechanism by which SARS-CoV-2 causes gastrointestinal symptoms remains unclear. The pathogenicity of COVID-19 is thought to be related to the angiotensin converting enzyme 2 (ACE2) receptor[29-32]. The SARS-CoV-2 virus consists of four main structural proteins: The spike (S) protein, membrane (M) proteins, nucleocapsid (N) proteins, envelope (E) proteins[33,34]. The S protein is the key component that mediates the entry of the virus into the host cell[35,36]. In the process of infecting cells, the S proteins of most coronaviruses are cleaved into S1 receptor-binding subunit and S2 fusion subunit by host cell Furin-like protease. S1 contains a receptor-binding domain (RBD) that plays an important role in recognizing and binding to the ACE2. Epigallocatechin gallate (EGCG), an active constituent of green tea, has been identified as a potential inhibitor of the RBD domain and other proteins of SARS-CoV-2[37]. The effect of green tea consumption may be explored for inhibition of S protein domains to prevent its binding with ACE2[38]. This may be particularly effective in the gastrointestinal tract, as the oral route implies maximum availability in the digestive tract. The S2 subunit is associated with the fusion of the viral membrane and the host cell membrane. The entry of coronavirus into susceptible cells is a complex process that requires ACE2 receptor binding and the enhancement of proteolytic distribution of protein S[36]. ACE2 is also closely related to the physiological processes of virus infection, virus killing, and natural immunity in the immune system (Figure 1). Transmembrane serine proteinase 2 (TMPRSS2) plays an indispensable role in the invasion and transmission of the virus for S protein priming. ACE2 is distributed in many tissues and organs of the human body. It is not only expressed in the heart, lung, kidney, and blood vessels but also in the digestive system, such as in the duodenum, jejunum, and liver[26]. Hoffmann et al[35] confirmed that the host cell entry of SARS-CoV-2 depends on the SARS-CoV receptor ACE2 and that the entry can be blocked by a clinically proven inhibitor of the cellular serine protease TMPRSS2. Xiao et al[12] observed the staining for viral nucleocapsid protein in the cytoplasm of gastric, duodenal, and rectum glandular epithelial cells and the positive staining for ACE2 and SARS-CoV-2 in the gastrointestinal epithelium from patients who tested positive for SARS-CoV-2 RNA in feces. Another study by Qian et al[39] also observed typical SARS-CoV-2 virus particles in the intestinal epithelial cells of a patient under electron microscopy and obtained direct evidence of active SARS-CoV-2 viral replication in the intestine. Virus particles were found in the cytoplasm of intestinal epithelial cells in a rectal adenocarcinoma patient with co-existing COVID-19 and the virions showed a typical morphology of coronavirus under electron microscopy[39]. These findings indicate that SARS-CoV-2 could directly target gastrointestinal cells, especially gastric and intestinal epithelial cells, leading to inflammatory reactions.

Figure 1.

A simplified diagram of the potential pathological mechanisms for gastrointestinal symptoms in severe acute respiratory syndrome coronavirus 2 infection. ACE2: Angiotensin converting enzyme-2; TMPRSS2: Transmembrane serine protease-2.

The “cytokine storm” has been considered as an essential mechanism of multiple organ dysfunction in COVID-19 patients. High expression of pro-inflammatory cytokines was detected in the serum of most COVID-19 patients, including interferon-γ, interferon-α, and interleukin (IL)-5[1]. The cytokine storm in COVID-19 infection is mainly caused by inducing varieties of pro-inflammatory signals through antigen-presenting cells and T cells against viral infection, and activated macrophages and dendritic cells[40-42]. These cells release chemokines and cytokines to attract more inflammatory cells, such as neutrophils, monocytes, and dendritic cells, which aggregate to the site of inflammation and activate the cascade of inflammatory response. The activated inflammatory cells release more cytokines, further worsening injury to the organs. The fierce cytokine-induced immunopathological attack contributes to the aggravation of patient's condition with a poorer prognosis.

LIVER INJURY IN COVID-19 PATIENTS

An increasing number of studies have reported liver damage in patients with COVID-19 and several have reported COVID-19 patients to have an increased risk of liver dysfunction[1,15,22,43,44]. COVID-19 patients may incur different degrees of liver function damage with elevated aspartate amino transaminase (AST), glutamate moderately amino transaminase (ALT), and total bilirubin (TBil)[45,46]. The risk of liver damage in severe and critically ill patients was higher than in mild patients in most studies. However, there was a subtle difference in the prevalence of lung injury and COVID-19 disease severity across studies, and the exact extent of liver involvement in the COVID-19 disease course remains uncertain[19,46]. In a meta-analysis of 12 studies comprised of 1267 patients, the pooled prevalence of liver injury was 19%, the prevalence of ALT elevation was 18%, the prevalence of AST elevation was 21%, and the prevalence of total bilirubin elevation was 6%[47]. Another cohort study of 1992 patients observed that 215 (11%) patients had an abnormal level of ALT or TBil[41]. Among patients with an abnormal ALT or TBil test result, 77% had a mild increase, 17% had a moderate increase, and 6% had a severe increase[48]. Additionally, the degree of liver function damage appears to correlate with the occurrence of gastrointestinal symptoms. Jin et al[47] reported that the incidence rate of elevated AST was significantly higher in patients with GI symptoms than in those without. Xu et al[49] observed moderate microvesicular steatosis and mild lobular and portal activity in the liver biopsy specimens of the patient with COVID-19, which provided evidence of liver injury. It is worth noting that the elevated prothrombin time among COVID-19 patients with digestive symptoms is common, and several studies have reported thromboembolism as a presenting clinical feature of COVID-19[50-53]. Therefore, liver function and the level of liver enzymes should be monitored early in COVID-19 patients with digestive symptoms (Figure 1).

COVID-19 may promote deterioration of liver function in patients who had been diagnosed with chronic liver disease previously and predict an increased risk for severe illness. Several studies have demonstrated that baseline liver disease severity is strongly associated with COVID-19-related morbidity and mortality; additionally, decompensated cirrhosis, hepatocellular carcinoma, and alcohol-related liver disease are risk factors for adverse outcomes from COVID-19[54-58]. A multi-center study involving 867 patients with chronic liver disease and COVID-19 reported that 14.0% of patients died, 60.4% were hospitalized, 23% were admitted to the ICU, and 7.7% developed hepatic decompensation[55]. Another study indicated that mortality was 32% in COVID-19 patients with a previous history of cirrhosis compared to 8% in those without (P < 0.001)[59]. Moon et al[60] found that 23.3% of patients with cirrhosis and COVID-19 were admitted to the ICU, 17.5% were treated with invasive ventilation, 18.6% were given non-invasive ventilatory support, 4.9% were given renal replacement therapy, and 39.8% died. Nowadays, accumulated data suggest that SARS-CoV-2 infection in patients with cirrhosis appears to be a particularly lethal combination. Compared to the patients without baseline liver disease, the patients with baseline liver disease are prone to unfavorable prognoses.

The mechanisms of liver injury in COVID-19 patients are complex. The higher overall mortality among patients with CLD and COVID-19 may be due to cirrhosis-associated immune dysfunction and metabolic syndrome[61,62], while it needs more research to confirm and explore.

IBD PATIENTS WITH SARS-COV-2 INFECTION

IBD, which mainly includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, nonspecific inflammatory disease with unclear etiology and pathogenesis. At present, intestinal microbial growth disorder, intestinal mucosal barrier injury, abnormal immune response in intestinal mucosal tissue, genetic susceptibility, and environmental factors are considered to be involved in the occurrence of intestinal inflammation. Patients with IBD are prone to frequent and severe infections and are often treated with corticosteroids, which are immunosuppressive agents. Whether the clinical presentation in patients with IBD differs from that of non-IBD people and the risk of SARS-CoV-2 infection or development of COVID-19 in patients with active IBD are uncertain[63]. GI symptoms including diarrhea and abdominal pain appear to be more frequent in COVID-19 IBD patients than in the COVID-19 non-IBD group. Aziz et al[64] reported an incidence of 0.3% for COVID-19 in their cohort of 9177 patients with IBD, an ICU admission rate of 8.6% in IBD patients with COVID-19, and a mortality rate of 6.3% in IBD patients with COVID-19. In a multicenter study from eight major gastrointestinal centers in Lombardy, Italy, IBD patients were not reported to have an increased risk of COVID-19 specific symptoms or more severe disease as compared with a control group of gastroenterology patients[65]. Another observational study confirmed that patients with IBD had a higher risk of COVID-19 incidence as compared to the general population and that tumor necrosis factor (TNF) antagonists may reduce the severity of COVID-19[66]. Singh et al[67] indicated no significant differences in the composite outcome of hospitalization or mortality between COVID-19 patients with IBD and those without. In addition, IBD patients with COVID-19 on long-term biologics or non-steroid immunomodulatory therapies did not have a higher risk of worse COVID-19 outcomes[67]. As the pandemic continues, it is essential to continue the collection of descriptive data to determine if patients with IBD are more vulnerable to SARS-CoV-2 infection.

Due to the frequent use of biologics and immune suppressors in patients with IBD, questions arose on whether IBD treatment can be continued during SARS-CoV-2 infection and whether a potential threat from the application of biologics and immune suppressors would be present for patients. Several studies implied that thiopurines, steroids, and oral salicylates could be associated with an increased risk of developing severe COVID-19[68,69]. Feldmann et al[70] indicated that anti-TNF antibodies might reduce some of the processes that occur during COVID-19 lung inflammation. As well, Brenner et al[68] found that tumor necrosis factor antagonists did not appear to be associated with severe COVID-19. Future studies are required to investigate the impact of anti-TNF antibodies. The American Gastroenterological Association (AGA) recommended that patients with IBD who have been infected with SARS-CoV-2 but have not developed COVID-19 should hold thiopurines, methotrexate, and tofacitinib and should delay the biological therapies; on the other hand, patients with IBD who develop COVID-19 should hold thiopurines, methotrexate, tofacitinib, and biological therapies during the viral illness as well and restart previous treatment after complete symptom resolution or negative PCR tests for SARS-CoV-2[63]. Olendzki et al[71] propounded that the Anti-Inflammatory Diet (IBD-AID) was effective in some IBD patients as an adjunct dietary therapy. In the absence of biological therapies, IBD-AID and some identified anti-inflammatory aliments such as ginger, turmeric, and cinnamon may be provided to IBD patients due to their potential inhibitory effects on key pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6[72].

MALNUTRITIONAL RISK AND NUTRITIONAL INTERVENTION IN COVID-19 PATIENTS

Malnutrition has been associated with outcomes of COVID-19 patients and is correlated with a higher risk of mortality[73]. In a study of 348 severe patients with COVID-19, 161 patients had mild malnutrition and 139 suffered moderate-severe malnutrition. The patients with moderate-severe malnutrition had a lower survival rate and higher mortality compared to those with normal or mild malnutrition[74]. One of the reasons is that COVID-19 induces an acute inflammatory response, which accelerates the consumption of nutrients, such as protein, micronutrients, and glucose[75,76]. Gastrointestinal symptoms caused by SARS-CoV-2 further impacted the nutrition absorption and exacerbated malnutrition. In addition, patients’ anxiety and poor appetite were also potential contributors to malnutrition[11,77,78]. Some studies show that elderly patients with COVID-19 have a higher risk of developing moderate-severe malnutrition and multi-system organ dysfunction due to their weaker immune function and chronic comorbidities[79,80].

The albumin levels are also decreased in COVID-19 patients and are positively correlated with the infection severity[81]. Zhang et al[82] found that 54.78% of COVID-19 patients (63/115) present hypoalbuminemia and among the severe COVID-19 patients, the percentage is 90.32%. Decreased protein synthesis, inadequate nutrition intake, increased tissue catabolism, and nutrient overconsumption may be potential contributors to hypoalbuminemia. Albumin is synthesized in the liver and has several key physiologic functions, such as maintaining colloid oncotic pressure, binding and transporting substances, and sustaining acid-base equilibrium[83]. During the acute stress response, inflammatory mediators such as C-reactive protein, fibrinogen, and alpha 1-antitrypsin are increased, whereas albumin synthesis is decreased[84,85]. Due to the inflammation-induced higher endothelial permeability, albumin can escape to the extravascular space through capillaries, leading to lower serum albumin levels. Hypoalbuminemia may be related to a worse clinical outcomes for COVID-19 patients[73,86-89]. In a retrospective analysis of 181 patients with COVID-19, patients with higher albumin levels on admission were associated with a lower risk of developing ARDS, admission to the ICU, and for every 1 g/dL increase of albumin, there is a 72% decreased risk of developing venous thromboembolism[90]. In another retrospective analysis, the researchers showed significant differences in the rates of hypoalbuminemia (odds ratio = 5.68) between deceased and recovered patients[91].

Previous studies also show that micronutrients play important roles in boosting the immune system[92-94]. Several studies have demonstrated that low levels or decreased intake of micronutrients such as vitamins A, E, B6, B12, Zn, and Se were associated with adverse clinical outcomes of COVID-19[95-99]. Im et al[100] reported that 24.0% of the patients with COVID-19 had severe vitamin D deficiency, and among 12 patients with respiratory distress, 91.7% were deficient in at least one nutrient. They speculated that vitamin D deficiency might be an important risk factor for the poor prognosis of COVID-19. In order to maximize anti-infection nutritional defense, we suggest the daily provision of vitamins and trace elements to malnourished patients with COVID-19. The European Society for Clinical Nutrition and Metabolism (ESPEN) recommended reasonable provision of vitamins and trace elements to benefit anti-infection nutritional defense[101].

Plenty of scientists have emphasized the significance of various nutritional interventions to regulate immune function[102]. Nutrition support is of great importance for patients with severe COVID-19, which can elevate immune function, decrease the incidence of multiple organ failure, and improve the prognosis of the disease. Therefore, the nutritional status of COVID-19 patients should be taken into consideration after admission.

PRECAUTIONS FOR PREVENTING SARS-COV-2 INFECTION DURING GI ENDOSCOPY PROCEDURES

With the growing spread of COVID-19, concerns should be raised with respect to guaranteeing safety for endoscopy operators. Exposure of the respiratory tract and/or digestive tract during endoscopic examination inevitably provides the risk for patients’ secretions and excretions to become potential sources of infection, which will significantly increase the probability of nosocomial cross-infection during the pandemic. Therefore, it is important that endoscopy centers pay great attention to indications that most vitally warrant digestive endoscopy procedures. Iacucci et al[103] recommended four different urgent scenarios that could necessitate endoscopy: Confirmation of a new diagnosis, especially in a moderate-to-severe scenario; a severe acute flare-up in patients with ulcerative colitis; partial bowel obstruction in patients with IBD, which could be secondary to neoplasia or ileocolonic anastomotic stricture; and cholangitis and jaundice in patients with known primary sclerosing cholangitis with dominant bile duct stricture. Further, endoscopists and assistants must strictly execute hospital infection control requirements and take corresponding classified protective measures according to the actual situation of patients. The AGA recommended the use of N95 (or N99 or PAPR) masks instead of surgical masks as part of appropriate personal protective equipment[104]. It is essential to evaluate the risk of patients with suspected or confirmed COVID-19 before endoscopy, in order to defer unnecessary endoscopies to minimize concomitant exposure.

CONCLUSION

Patients with COVID-19 may also develop various gastrointestinal symptoms, which may be pre-existing or not accompanied by respiratory symptoms. The importance of recognizing and diagnosing the occurrence of gastrointestinal symptoms is immeasurable. Clinicians should be cautious in the management of this highly infectious disease and recognize that gastrointestinal symptoms may be characteristic of COVID-19. Careful consideration of gastrointestinal symptoms may enable early COVID-19 detection, diagnosis, isolation, and intervention. Evidence on fecal-oral contagion of SARS-CoV-2 continues to increase. It is therefore important to step up infection control measures to avoid fecal-oral transmission and standardize health care operational processes.